Episode 44 – We’ve got the MS drugs, but what’s next?
We celebrated with the Multiple Sclerosis community as TG Therapeutics announced in the final days of 2022 that the FDA approved Briumvi (ublituximab-xiiy), putting the number of available MS disease-modifying therapies to more than 25. Hooray, right? Of course! But…
